Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker Corporation has successfully installed two novel, compact 1.0 GHz NMR systems for structural and molecular biology applications at RIKEN in Japan and the University of Barcelona in Spain, ahead of schedule in late 2022. These Ascend Evo 1.0 GHz NMR systems operate at 4.2 Kelvin and consume approximately 65% less liquid helium compared to previous models. The compact design eases site installation and is expected to enhance research in biomolecular dynamics. The installations are already generating valuable scientific data, contributing to advancements in life sciences and clinical research.
Bruker Corporation (Nasdaq: BRKR) will report its fourth quarter and fiscal year 2022 financial results before market opening on February 9, 2023. A conference call and webcast will follow at 8:30 a.m. EST to discuss these results and current business trends. Investors can listen to the webcast at Bruker's Investor Relations website. Pre-registration for the call is available to streamline access. A replay of the conference call will be accessible from March 9, 2023, along with a slide presentation available shortly before the webcast begins.
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of ACQUIFER Imaging GmbH, enhancing its bioimaging solutions. This acquisition includes ACQUIFER's HIVE data management system, which supports high-performance computing and big-data storage for microscopy applications. Additionally, the IM04 Imaging Instrument expands Bruker's portfolio into high-content screening. The financial details of the deal were not disclosed, but it is expected to enhance Bruker's capabilities in life science research, particularly in organoid and stem cell studies.
Bruker has announced a strategic partnership with Biognosys, acquiring a majority stake to enhance access to Biognosys' CRO services and Spectronaut® software for proteomics research. The partnership aims to support drug discovery, biomarker development, and clinical trials, with plans to establish a new advanced proteomics facility in the US. The collaboration leverages Bruker's technology alongside Biognosys' expertise, promising improved proteomics capabilities and expanded services for their biomarker and biopharma clientele.
Bruker Corporation (Nasdaq: BRKR) will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 AM EST in San Francisco. Key executives, including Chairman Frank Laukien and CFO Gerald Herman, will represent the company. A live audio webcast of the presentation can be accessed via the Investor Relations section of Bruker's website, with a replay available for 30 days thereafter. Bruker specializes in high-performance scientific instruments that support significant advancements in life sciences and material sciences.
Bruker Corporation (Nasdaq: BRKR) announced significant multi-year contracts valued at approximately $50 million with its majority-owned RI Research Instruments GmbH and Bruker Energy & Supercon Technologies (BEST). These contracts involve supplying key technology components for major fusion projects in Europe and Asia. The projects include providing Inner Vertical Targets for the ITER fusion initiative and high-current density RRP® superconductors for a tokamak project. This advancement positions Bruker to play a vital role in future sustainable energy solutions.
Kiyatec Inc. has successfully closed its Series C funding round, raising US$18 million led by new investor Bruker (BRKR) and supported by LabCorp (LH) and others. The funds will enhance the adoption of Kiyatec's clinical testing and preclinical pharma services, vital for improving cancer treatment outcomes. Kiyatec's 3D-Predict™ Glioma test has shown significant clinical correlations, allowing better therapy selection for glioblastoma patients. The company aims to grow its revenue through innovative testing and drug development partnerships.
Bruker Corporation (Nasdaq: BRKR) has signed a definitive agreement to acquire Neurescence Inc., known for its innovative Multiscopes™ technology that allows simultaneous multi-region optical neuroimaging. Neurescence's Chromatone™ system, which minimizes weight on animals, enhances the investigation of neuron functions. This acquisition strengthens Bruker's portfolio in animal imaging and expands its capabilities in neuroresearch. Financial terms of the deal were not disclosed, but the acquisition is expected to leverage synergies with Bruker's existing products, positioning the company as a leader in this field.
Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend of
Bruker Corporation (Nasdaq: BRKR) announced its acquisition of Inscopix, a leader in miniaturized microscopes for neuroscience research. Inscopix's innovative equipment has been deployed in 600+ institutions globally, facilitating advances in understanding neurological disorders. This acquisition is expected to enhance Bruker's in-vivo imaging capabilities, combining high-resolution multiphoton microscopy with Inscopix’s advanced miniaturized technology. Inscopix's projected FY 2022 revenue is $20-25 million, with expectations of continued double-digit growth.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
